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Specific high-affinity binding sites for *2SI-a-bungarotoxin and (-)-PHInicotine have been measured in rat 
brain and locust (Schistocerca gregaria) ganglia. The binding sites for lZsI-a-bungarotoxin had similar Kd 
values of 1.5 x 10m9 and 0.8 x lO-g M for rat and locust preparations, respectively; the corresponding values 
for the (-)-rH]nicotine-binding site were 9.3 x 1O-9 and 1.7 x lo-’ M. Methyllycaconitine (MLA) potently 
inhibited 1251-a-bungarotoxin binding in both rat and locust. MLA was a less effective inhibitor of 
(-)-PHInicotine binding whereas (+)-anatoxin-a was a very potent inhibitor at this site in the rat but not 
in the locust. These data suggest that (+)-anatoxin-a is a useful probe for the high-affinity nicotine-binding 
receptor in vertebrate brain, whereas MLA is a preferential probe for the subclass of receptor that binds 
a-bungarotoxin. 
a-Bungarotoxin; Nicotine; Methyllycaconitine; Anatoxin-a; Nicotinic receptor; (Rat brain, Locust ganglion) 
1. INTRODUCTION 
There is a growing body of evidence supporting 
the idea that there are nicotinic acetylcholine 
receptors (nAChR) in vertebrate brain which are 
genetically related to but pharmacologically 
distinct from the well-characterized peripheral 
nAChR [l]. It is also clear that there is 
heterogeneity of such nAChRs within the brain; 
for example, a distinction can be made between 
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proteins that interact strongly with cy-bungarotoxin 
and those that show high-affinity (-)-nicotine 
binding [2,3]. Such pharmacological distinctions 
are paralleled in molecular genetic studies where 
evidence is emerging that neurones may have 
families of related genes coding for nAChRs [4]. In 
insects, cholinergic transmission is confined to the 
central nervous system and most published work 
has been based on the assumption that cy- 
bungarotoxin binding defines this receptor. The 
pharmacological properties of the insect nAChR, 
however, indicate a specificity that is not identical 
to that of the vertebrate [5]. In fact, there are 
limited structural data available for insect recep- 
tors and controversy exists regarding the numbers 
and types of subunits present [6]. 
Abbreviations: nAChR, nicotinic acetylcholine receptor; We have compared the binding of 125I-,- 
MLA, methyllycaconitine bungarotoxin and ( -)-[3H]nicotine to rat and 
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locust neuronal tissue and have characterized the 
pharmacology of this binding using several 
nicotinic ligands. In particular, we have made use 
of two natural toxins, methyllycaconitine (MLA) 
and ( +)-anatoxin-a. MLA, found in the seeds of 
the plant Delphinium brownii, is a potent insec- 
ticide [7] but is only moderately effective as an an- 
tagonist at the mammalian neuromuscular 
junction [8]. (+)-Anatoxin-a, a product of the 
freshwater alga Anabaena flos-aquae, is a potent 
agonist at the vertebrate neuromuscular junction 
and at the central nervous system and closely 
resembles acetylcholine in its channel-activating 
properties [9-l 11. 
2. MATERIALS AND METHODS 
2.1. Materials 
Adult locusts (Schistocerca gregaria) were pur- 
chased from Cambridge Biosciences (Cambridge, 
England). Torpedo nAChR was prepared as 
described [121. (- )-[N-methyl-3H]Nicotine (78 Ci/ 
mmol) and Na? were purchased from Amer- 
sham International (Amersham, England). CY- 
Bungarotoxin was obtained from Sigma (Poole, 
England) and was iodinated to a specific activity of 
700 Ci/mmol [ 121. Both ( + )- and ( - )-anatoxin-a 
were synthesized by one of us (H.R.). MLA 
(citrate salt) was a gift from Dr M.H. Benn 
(Department of Chemistry, University of Calgary, 
Alberta). ( + )-Nicotine di-( - )-tartrate was pro- 
vided by Dr Barlow (Department of Pharma- 
cology, University of Bristol, Bristol, England) 
and dihydro-&erythroidine was supplied by Dr 
R.G. Benfield (Merck Sharp & Dohme, Hoddes- 
don, England). Mecamylamine was provided by Dr 
M. Caulfield (Glaxo, England) and pentolinium 
and pempidine were supplied by May & Baker 
(Dagenham, England). 1 ,l-Dimethyl4_piperazi- 
nium (DMPP) was purchased from Aldrich. Other 
drugs were purchased from Sigma. All drug solu- 
tions were prepared freshly on the day of assay 
with the exception of a-bungarotoxin and ( +)- 
and ( -)-anatoxin-a which were stored frozen as 
aqueous stock solutions at concentrations of 2.5 x 
10m4, 1 x 10e4 and 5 x 10e2 M, respectively. 
2.2. Preparation of rat brain P2 membrane 
fraction 
A P2 membrane fraction was prepared from 
whole brains of adult, male Wistar rats (minus the 
cerebellum). The tissue was homogenized (10070, 
w/v) in 0.32 M sucrose solution, pH 7.4, contain- 
ing 1 mM EDTA, 0.1 mM phenylmethylsulphonyl 
fluoride and 0.01% (w/v) sodium azide and the 
suspension was centrifuged at 1000 x g for 10 min. 
The supernatant was decanted and retained on ice. 
The pellet was resuspended in 0.32 M sucrose 
(5 ml/g original wet wt) and recentrifuged. The 
supernatants were combined and centrifuged at 
12000 x g for 30 min to give a P2 pellet. This was 
resuspended in 50 mM potassium phosphate buf- 
fer, pH 7.4, containing protease inhibitors as 
above, to give a final volume of 2.5 ml/g original 
wet wt and washed twice by centrifugation and 
resuspension. 
Table 1 
Characteristics of radioligand-binding sites in rat brain and locust ganglion PZ 
membrane preparations 
( -)-[3H]Nicotine ‘251-cY-Bungarotoxin 
Rat Locust Rat Locust 
brain ganglia brain ganglia 
Kd (nM) 9* 3 130% 3 1.5 + 0.7 0.8” 
B,,, (pmol/g protein) 108 + 18 4055 + 403 63 k17 1200” 
a Single experiment carried out in triplicate 
Data are from linear regression analyses of Scatchard plots and are means f range 
or SE of 2 or 4 independent determinations carried out in triplicate 
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2.3. Preparation of locust ganglion P2 membrane 
fraction 
2-week old adult locusts were used for all ex- 
periments. A membrane fraction was prepared 
from supraesophageal ganglia exactly as in [13]. 
2.4. Ligand-binding assays 
( -)-[3H]Nicotine binding to P2 membranes was 
carried out similarly using rat and locust tissues, 
but in the former case the membrane suspension 
was first diluted 5-fold in 50 mM potassium 
phosphate buffer, pH 7.4. Tissue samples 
(0.25 ml) were incubated with ( -)-[3H]nicotine 
(10 nM for rat and 50 nM for locust unless other- 
wise stated) for 30 min at 20°C in the presence and 
absence of excess unlabelled nicotine (10e3 M) to 
determine nonspecific binding. In competition 
assays, tissue samples were preincubated with 
serial dilutions of drug for 10 min at 20°C prior to 
addition of radioligand. The samples were chilled 
on ice, diluted with 2 ml ice-cold phosphate- 
buffered saline (10 mM potassium phosphate, pH 
7.4, containing 140 mM NaCl) and rapidly filtered 
under vacuum on Whatman GFC filters pre- 
soaked in 0.3% (w/v) polyethyleneimine [14]. The 
filters were washed twice with 2 ml phosphate- 
buffered saline; filtration and washing was ac- 
complished within 20 s. The filters were counted in 
5 ml Optiphase ‘safe’ scintillant in a Packard scin- 
tillation spectrometer. 
1251-cu-Bungarotoxin b ding to P2 membrane 
fractions was measured using a centrifugation 
assay [ 151. For the locust P2 membrane fraction, 
samples (0.25 ml) were incubated in exactly the 
same way as rat samples. However, the unbound 
radioligand was removed by filtration on GFC 
filters pre-soaked in polyethyleneimine (0.3%, 
w/v). The filters were measured for radioactivity 
in an LKB 1280 Ultrogamma counter. 
1251-a-Bungarotoxin binding to Torpedo 
nAChR was carried out as described [3]. 
3. RESULTS 
3.1. Saturable binding of (-)-tH_lnicotine and 
‘2SI-cu-bungarotoxin 
Saturation binding experiments were performed 
on the P2 membrane fractions from rat brain and 
locust ganglia using ( -)-[3H]nicotine and 1251_cy- 
bungarotoxin. The binding data for both tissues 
are listed in table 1. The & for ( -)-[3H]nicotine 
binding to locust ganglion P2 membranes was 
higher than to membranes from rat brain. 125I-,- 
Bungarotoxin bound to the locust tissue with high 
affinity comparable to that for binding to rat 
brain. In the case of locust membranes, the B,,, 
values for both ligands were an order of magnitude 
more than those observed in rat brain P2 mem- 
branes (table 1). In both tissues, B,,, for (-)- 
[3H]nicotine binding was 2-4-times that for 1251- 
a-bungarotoxin binding to the same membrane 
preparation. 
(a) 
Cd) 
Log concentration displacing ligand (M) 
Fig.1. Competition binding assays with MLA and 
anatoxin-a. Competition assays for (a) ( -)-[3H]nicotine 
and (b) 1Z51-cu-bungarotoxin b ding to rat brain P2 
membranes, and (c) ( -)-[3H]nicotine and (d) ‘2sI~- 
bungarotoxin binding to locust ganglion P2 membranes 
were carried out in the presence of MLA (A), ( +)- 
anatoxin-a (0) and (-)-anatoxin-a (0). Results are 
taken from a representative xperiment, with each ligand 
concentration assayed in triplicate. 
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3.2. Inhibition of binding by MLA and 
(+)-anatoxin-a 
In competition assays, (+ )-anatoxin-a was a po- 
tent competitor of ( -)-[3H]nicotine binding to rat 
brain P2 membranes (fig-la), being at least an 
order of magnitude more potent than ( - )-nicotine 
(table 2). The toxin was correspondingly more po- 
tent than (-)-nicotine in blocking 1251~- 
bungarotoxin binding to rat brain (fig. lb) but both 
agonists have micromolar rather than nanomolar 
affinities at this site (table 2). In locust ganglia, 
( + )-anatoxin-a displayed a 5-l O-fold higher 
potency at the “‘I-a-bungarotoxin-binding site 
(fig.ld) compared to the corresponding binding 
site in rat brain (fig. 1 b), but the ( -)-[3H]nicotine- 
binding site in locust was largely insensitive to ( + )- 
anatoxin-a (fig.lcj. At each of these sites (-)- 
anatoxin-a had a much weaker affinity, and the ac- 
tivity observed with the ( -) enantiomer can be 
ascribed to residual traces of (+)-anatoxin-a. 
MLA had a high affinity for the locust neuronal 
“‘1-cY-bungarotoxin-binding site (fig, Id) and was 
similarly potent in competing for the 1251-~- 
bungarotoxin-binding site in rat brain (fig. lb). 
However, in competition assays for 1251-cy- 
bungarotoxin binding to purified Torpedo 
nAChR, MLA had a Ki of 1.15 + 0.65 x 10e6 M 
(n = 3). MLA was a much weaker competitor of 
( -)-[3H]nicotine binding to both rat brain (fig. la) 
and locust ganglia (fig.Ic). 
3.3. Pharmacological specificity of (-)-PHJ- 
nicotine and ‘251-wbungarotoxin sites 
A further comparison of the binding sites for 
Table 2 
Inhibition of ( -)-13H]nicotine and ‘251-cY-bungarotoxin bi ding to rat brain and 
locust ganglion P2 membranes by cholinergic drugs 
Displacing ligand Ki (M) 
( -)-[3H]Nicotine “‘1-cY-Bungarotoxin 
Rat Locust Rat Locust 
brain ganglia brain ganglia 
( + )-Anatoxin-a 3.4 x 10~1° > W5 9.1 x 1O-8 1.6 x lo-’ 
( - )-Anatoxin-a 3.9 x lo-’ > 10-3 2.1 x 1o-5 1.0 x 1o-4 
( - )-Nicotine 1.5 x 10-E 7.7 x lo-’ 5.1 x 1o-6 5.1 x lo-’ 
( + )-Nicotine 4.7 x 1o-6 1.5 x 1o-5 
MLA 3.7 x 1O-6 2.5 x 1O-4 1.4 x 1O-9 1.8 x 1O-8 
DMPP 4.0 x lo-’ 2.0 x 1o-4 2.3 x 1O-6 3.8 x lo-” 
Dihydro-fl-erythroidine 1.3 x 10-6 1.8 x 1om4 2.5 x 1O-5 1.3 x lo-’ 
Decamethonium 1.2 x 1o-4 2.0 x 1o-4 
Hexamethonium 3.9 x 10-3 8.8 x 1o-4 
Pentolinium 3.3 x 1o-4 1.5 x 1o-3 
Pempidine 2.6 x 1O-3 2.5 x 1O-3 
Mecamylamine 1.0 x 10-2 1.5 x 1o-3 
cr-Bungarotoxin > 10-6 > 1o-6 1.0 x 1O-9 8.9 x 1O-9 
Atropine 8.2 x 1O-5 
TEA > 10-3 > 1o-4 
Competition binding assays were performed as described in section 2 using (-)- 
[3H]nicotine at 10 nM (rat brain) or 50 nM (locust ganglia) and 125I-o- 
bungarotoxin at 1 nM. ICse values were derived from linear transformations of 
dose-response curves; Ki values were derived from IC50 values [16], assuming Kd 
values for [‘HInicotine binding to P2 membranes of 8.0 nM (rat brain) or 130 nM 
(locust ganglia), and 1 .O nM for ‘251-a-bungarotoxin binding to both tissues. Data 
are the means of at least 3 independent determinations for rat brain membranes and 
2 determinations for locust ganglia, carried out in triplicate 
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both ( -)-[3H]nicotine and “‘1-cY-bungarotoxin 
was undertaken by determining a wider phar- 
macological profile (table 2). The cu-bungarotoxin- 
binding site in both tissues displayed comparable 
drug sensitivities with moderate competition by 
nicotinic agonists, including nicotine, and poor in- 
hibition by antagonists, with the exception of LY- 
bungarotoxin itself and dihydro$-erythroidine. 
The invertebrate site exhibited slightly higher sen- 
sitivities to most of the drugs tested when com- 
pared with the rat brain site. In contrast, 
( -)-[3H]nicotine-binding sites in the two tissue 
preparations differed markedly; whereas binding 
to mammalian brain was generally very sensitive to 
nicotinic agonists, ( -)-[3H]nicotine binding to the 
invertebrate preparation was largely unaffected by 
all the drugs tested. Furthermore, [3H]nicotine 
binding to rat brain membranes was characterized 
by considerable stereoselectivity for the (-) enan- 
tiomer of nicotine [2,3]. This site in locust ganglion 
membranes displayed little preference for (-)- 
nicotine (table 2) and had low sensitivity to 
nicotinic agonists. Indeed, in the locust the cy- 
bungarotoxin-binding site showed greater stereo- 
selectivity for (-)-nicotine than did the nicotine- 
binding site. 
4. DISCUSSION 
(+)-Anatoxin-a and MLA interact quite dif- 
ferently with the ( -)-[3H]nicotine-binding site and 
the ‘*‘I-a-bungarotoxin-binding site in rat brain. 
At the neuromuscular junction, ( + )-anatoxin-a is 
a potent nicotinic agonist and its activity is 
stereospecific, residing in the ( +) enantiomer of 
the alkaloid [9, lo]. We have recently reported [l l] 
that (+)-anatoxin-a activates neurones in the hip- 
pocampus and brain stem. We show here that the 
high-affinity ( -)-[3H]nicotine-binding site in rat 
brain is particularly sensitive to (+ )-anatoxin-a 
(fig.la), whereas the corresponding site in locust 
ganglia is virtually insensitive (fig.lc). At the CY- 
bungarotoxin site, ( + )-anatoxin-a was found to be 
an effective inhibitor of binding in both locust 
ganglia and rat brain. A previous study on rat 
brain showed that racemic anatoxin-a had an even 
lower affinity for the muscarinic site labelled by 
[3H]quinuclidinyl benzilate [17]. 
MLA has a high affinity (Ki = 2.5 x lo-” M) 
for the a-bungarotoxin-binding site in housefly 
heads [7] and an EDso value in the micromolar 
range at the mammalian neuromuscular junction 
[8]. We observed that in rat brain MLA is much 
more effective at the a-bungarotoxin-binding site 
(fig.lb) than at the nicotine site (fig.la). This is the 
converse of the effects seen with (+)-anatoxin-a. 
In locust ganglia however, the a-bungarotoxin site 
was equally sensitive to MLA and anatoxin-a 
(fig.ld) while the nicotine site was insensitive to 
both toxins (fig.lc). From these results, it seems 
that MLA is a highly selective toxin for the (Y- 
bungarotoxin-binding site, a preference previously 
only demonstrated by the snake venom (Y- 
neurotoxins. Moreover, MLA also displays a much 
higher affinity for the neuronal cu-bungarotoxin- 
binding site than for the nAChR in Torpedo, sug- 
gesting that it may be generally useful as a 
preferential probe for the a-toxin receptor in the 
CNS of both vertebrates and invertebrates. Our 
results for ‘*‘I-cr-bungarotoxin binding to locust 
ganglion P2 membranes are comparable to the 
published values for other insects [5] and are 
similar to those for rat brain P2 membranes. In 
vertebrates cy-bungarotoxin is a potent and well- 
characterized nicotinic antagonist only at 
peripheral sites; the functional significance of 
neuronal cY-bungarotoxin-binding sites is un- 
known. In contrast to mammalian brain, a 
blockade of excitatory synaptic transmission by (Y- 
bungarotoxin has been demonstrated elec- 
trophysiologically in the cockroach CNS [18]. 
However, other workers have reported central 
nicotinic responses in insects that are insensitive to 
a-bungarotoxin [ 191. 
Unlike the a-bungarotoxin-binding site, the 
( -)-[3H]nicotine-binding sites differ markedly in 
rat brain and locust ganglia. Thus, in rat brain the 
binding of ( -)-[3H]nicotine exhibited greater sen- 
sitivity to many of the nicotinic agonists than did 
the ‘*‘I-cr-bungarotoxin-binding site, further em- 
phasizing the presence of two distinct sites in this 
tissue. This is in agreement with autoradiographic 
studies on rat brain slices using these two ligands 
which show that the distribution of (-)- 
[3H]nicotine- and “‘1-a-bungarotoxin-binding 
sites is distinctly different [20,21] and with 
demonstrations that the two binding sites are 
associated with different proteins [3,22]. It has 
also been shown that the rat brain high-affinity 
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( -)-[3H]nicotine-binding site has very similar 
characteristics to a [3H]acetylcholine-binding site 
[2,23]. The behavior of the ( -)-[3H]nicotine- 
binding site in the locust is in marked contrast; 
thus ( -)-[3H]nicotine binds with lower affinity 
and the binding did not fully saturate over the 
range O-100 nM. The locust site exhibited very low 
affinity for all the ligands used and only (-)- and 
( + )-nicotine were effective in displacing the bound 
( -)-[3H]nicotine; even then the stereospecificity of 
their effectiveness was very slight compared to the 
rat brain site [3]. 
Whereas in the rat brain the nicotine-binding site 
is a strong candidate for a physiological nAChR 
(see [l]), in the locust this seems not to be the case. 
Nicotine certainly possesses insecticidal properties 
but our findings with MLA, which is a more potent 
insecticide [7] and a more potent inhibitor of lz51- 
a-bungarotoxin binding, suggests that the target is 
the a-bungarotoxin-binding site rather than the 
( - )-[3H]nicotine-binding site. Thus we would con- 
clude that in the insect ganglia there is an 
acetylcholine receptor labelled by ‘*‘I-cw-bungaro- 
toxin that shares pharmacological specificity with 
its mammalian counterparts in peripheral and cen- 
tral nervous systems. Whether such a receptor is, 
in evolutionary terms, the parent protein of the 
present-day vertebrate receptors [24] or whether 
both vertebrate and insect nAChRs have evolved 
from a single more ancient protein remains to be 
elucidated. The novel neurotoxins MLA and (+)- 
anatoxin-a are likely to be useful probes in the 
quest for a better understanding of the relation- 
ships between neuronal nicotinic receptors. 
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